Comparison Between 7 and 14 Day Primaquine Combined With Dihydroartemisinin-piperaquine or 3 Day Chloroquine Radical Cure of P. Vivax (BPD)
Vivax Malaria
About this trial
This is an interventional treatment trial for Vivax Malaria focused on measuring Vivax, Chloroquine, Primaquine, Dihydroartemisinin-Piperaquine
Eligibility Criteria
Inclusion Criteria:
- ≥ 6 months old
- Microscopic diagnosis of Plasmodium vivax malaria mono-infection
- Participant or parent/guardian is willing and able to give informed consent for participation in the study
- Able (in the Investigators opinion) and willing to comply with all study requirements.
Exclusion Criteria:
- Severe malaria
- History of allergy or adverse reaction to artesunate, piperaquine, chloroquine, or primaquine
- Blood transfusion in the past 3 months
- G6PD deficiency by rapid test
- Hematocrit ≤ 25%
- Pregnancy at the time of screening
- Breastfeeding an infant < 6 months old
- Presence of any condition which in the judgement of the investigator would place the subject at undue risk or interfere with the results of the study
Sites / Locations
- Shoklo Malaria Research Unit
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Experimental
Experimental
Active Comparator
Active Comparator
DHA-P 7 days
DHA-P 14 days
Chloroquine 7 days
Chloroquine 14 days
Dihydroartemisinin-piperaquine + Primaquine: DHA-P 7mg/kg/day dihydroartemisinin and 55mg/kg/day piperaquine daily for 3 days and Primaquine 1 mg/kg once daily for 7 days
Dihydroartemisinin-piperaquine + Primaquine: DHA-P 7mg/kg/day dihydroartemisinin and 55mg/kg/day piperaquine daily for 3 days Primaquine 0.5 mg/kg daily for 14 days
Chloroquine + Primaquine: Chloroquine 10, 10, 5 and Primaquine 1 mg/kg once daily for 7 days
Chloroquine + Primaquine: Chloroquine 10, 10, 5 and Primaquine 0.5 mg/kg daily for 14 days